中文名称: 洛伐他汀
中文同义词: (S)-2-甲基丁酸-(1S,3S,7S,8S,8aR) 1,2,3,7,8,8a-六氢-3,7-二甲基-8-{2-[(2R,4R)-4-羟基-6-氧代-2-四氢吡喃基]-乙基}-1-酯;洛伐司他汀;洛伐他汀;洛伐它丁;(1S,3R,7S,8S,8ΑR)-1,2,3,7,8,8Α-HEXAHYDRO-3,7-DIMETHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-Y1]ETHYL]一1一NAPHTHYL(S)-2-METHYLBUTYRATE;(1S,3R,7S,8S,8ΑR)-1,2,3,7,8,8Α-六氢-3,7-二甲基-8-[2.[(2R,4R)-四氢-4-羟基-6-氧代-2H-吡喃-2-基]乙基]-1-萘基(S)-2-甲基丁酸酯;洛伐他丁(洛伐司他汀);洛伐他丁
英文名称: Lovastatin
英文同义词: )ethyl]-1-naphthalenylester;[1s-[1alpha(r*),3alpha,7beta,8beta(2s*,4s*),8abeta]]-2-methylbutanoicacid1,2,;1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobuty;2-methyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-butanoicaci;3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl;3r,7s,8s,8ar)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[2r,4r)-tetrahydro-(1;4-hydroxy-6-oxo-2h-pyran-2-yl)ethyl)-1-naphthalenylester,(1s-(1-alpha-(r*),3;4-hydroxy-6-oxo-2h-pyran-2-yl]ethyl]-1-naphthalenyl(s)-2-methyl-butyrate
CAS号: 75330-75-5
分子式: C24H36O5
分子量: 404.54
用途 新型血脂调节药-HMG-CoA(β-羟基，β-甲基-戊二酸单酰辅酶A)还原酶抑制剂。能明显降低血清总胆固醇的浓度，口服后被水解成相应的β-羟基酸，3-羟基-3-甲基戊二酰辅酶A还原酶，而抑制胆固醇合成。临床用于杂合型家族性高胆固醇血症、严重及轻型原发性高胆固醇血症，还可作饮食疗法辅助药物，减少过高的胆固醇和低密度蛋白胆固醇水平。
用途 心血管系统用药，能阻止动脉硬化的发展、减少心肌梗塞等的发病危险
原料药 > 循环系统用药 > 调节血脂药 > 洛伐司他汀
质量标准：EP7.0 USP32

Chinese name: lovastatin
Chinese Synonyms: (S) -2--methyl-butyric acid - (1S, 3S, 7S, 8S, 8aR) 1,2,3,7,8,8a- 3,7-dimethyl-8-hexahydro-{2 - [(2R, 4R) -4--hydroxy-6-oxo-2-tetrahydropyranyl] - ethyl} -1 ester; lovastatin statins; lovastatin; lovastatin; (1S, 3R, 7S, 8S, 8ΑR) -1,2,3,7,8,8Α-HEXAHYDRO-3,7-DIMETHYL-8- [2 - [(2R, 4R) -TETRAHYDRO-4-HYDROXY- 6-OXO-2H-PYRAN-2-Y1] ETHYL] a a a NAPHTHYL (S) -2-METHYLBUTYRATE; (1S, 3R, 7S, 8S, 8ΑR) -1,2,3,7,8,8Α- 3,7-dimethyl-hexahydro -8- [2 [(2R, 4R) -. tetrahydro-4-hydroxy-6-oxo-pyran-2-yl -2H-] ethyl] -1 naphthyl (S) -2- methylbutyrate; lovastatin (lovastatin statins); lovastatin
English name: Lovastatin
English Synonyms:) ethyl] -1-naphthalenylester; [1s- [1alpha (r *), 3alpha, 7beta, 8beta (2s *, 4s *), 8abeta]] - 2-methylbutanoicacid1,2,; 1,2,6 , 7,8,8a-hexahydro-beta, delta-dihydroxy-2,6-dimethyl-8- (2-methyl-1-oxobuty; 2-methyl-, 1,2,3,7,8,8a-hexahydro -3,7-dimethyl-8- (2- (tetrahydro-butanoicaci; 3,7,8,8a-hexahydro-3,7-dimethyl-8- [2- (tetrahydro-4-hydroxy-6-oxo-2h -pyran-2-yl; 3r, 7s, 8s, 8ar) -1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8- [2- [2r, 4r) -tetrahydro- (1; 4-hydroxy-6-oxo-2h-pyran-2-yl) ethyl) -1-naphthalenylester, (1s- (1-alpha- (r *), 3; 4-hydroxy-6-oxo-2h- pyran-2-yl] ethyl] -1-naphthalenyl (s) -2-methyl-butyrate
CAS: 75330-75-5
Formula: C24H36O5
Molecular Weight: 404.54
Novel lipid regulating drugs uses -HMG-CoA (β- hydroxy, β- methyl - glutaryl-coenzyme A) reductase inhibitor. Can decrease serum total cholesterol concentrations after oral administration β- hydrolyzed to the corresponding hydroxy acid, 3-hydroxy-3-methylglutaryl coenzyme A reductase and inhibit cholesterol synthesis. Clinic for heterozygous familial hypercholesterolemia, severe and light primary hypercholesterolemia, but also for dietary adjunct therapy to reduce high cholesterol and low-density lipoprotein cholesterol levels.
Use the cardiovascular system drugs, can prevent the development of atherosclerosis and reduce the risk of myocardial infarction, etc.
API> circulatory system drugs> lipid regulating drugs> lovastatin statins
Quality Standard: EP7.0 USP32

Package price 545 / kg 1kg 850 / kg